Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33160424" target="_blank" >RIV/61989592:15110/16:33160424 - isvavai.cz</a>
Result on the web
<a href="https://www.spandidos-publications.com/10.3892/ol.2015.4017" target="_blank" >https://www.spandidos-publications.com/10.3892/ol.2015.4017</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/ol.2015-4017" target="_blank" >10.3892/ol.2015-4017</a>
Alternative languages
Result language
angličtina
Original language name
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
Original language description
The aim of the present study was to examine the changes in intima-media thickness (IMT) and myocardial perfusion in association with other laboratory risk factors for atherosclerosis in patients treated with therapy that targeted vascular endothelial growth factor (VEGF). IMT, myocardial perfusion and laboratory risk factors of atherosclerosis were studied in 58 patients with metastatic colorectal carcinoma or metastatic renal cell carcinoma prior to and at 3-monthly intervals during anti-VEGF treatment. Compared with the pretreatment IMT, the results indicated that the IMT was consistently increased during therapy in the two patient groups. Patient blood pressure and concentration of troponin T increased transiently. An increase in the concentration of high-density lipoprotein cholesterol and decrease in the concentrations of C-reactive protein and homocysteine were also observed. Novel myocardial ischemia was evident in individual patients. In conclusion, anti-VEGF therapy affects the laboratory risk factors of atherosclerosis and results in an acceleration of atherosclerosis, as demonstrated by increased IMT.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LO1304" target="_blank" >LO1304: Support of suistainability of the Institute of Molecular and Translational Medicine</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Oncology Letters
ISSN
1792-1074
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
2
Country of publishing house
GR - GREECE
Number of pages
6
Pages from-to
939-944
UT code for WoS article
000369554200005
EID of the result in the Scopus database
—